Kythera's lead candidate appears to reduce chin fat in Phase II
This article was originally published in Scrip
Executive Summary
Kythera Biopharmaceuticals' lead product candidate, ATX-101, appeared to have been successful in reducing submental (under-the-chin) fat in two Phase II trials.